...esearch suggests that stress may activate immune c...disease. The related report by Joachim et al., "S...in Skews Dendritic Cells towards Maturation and Mi...ppears in the November issue of The American Jour...l of defense to infection, serving not only as a p...
...t to guide their nest-mates to good food sources, ...y of London. , For any animal, finding food on it...l animals such as bees reduce these problems by in...iting, them to the search. , Honeybees use their ...irection of a food source. But bumblebees can,t co...
...bies in Germany are born with alcohol-related defe...k alcohol regularly during the pregnancy. The cons...t into adulthood. The various forms of fetal alcoh...icians Hans-Ludwig Spohr and Hans-Christoph Steinh...International ( Dtsch Arztebl Int 2008; 105[41]:...
Other Biology News:Stress may make you itch 2(Date:11/19/2009)... , MALVERN, Pa. and WALTHAM, Mass., Nov. 19 /PR... Decision Resources find that the leading driver o...Europe is broad-spectrum activity against gram-pos...ety of organisms that can cause nosocomial pneumon...look primarily for agents that provide appropriate...
(Date:11/19/2009)..., MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeu...patient in a randomized Phase 2B study of AEG35156...velopment for multiple oncology indications. ,,...se 2 Study of the X-Linked Inhibitor of Apoptosis ...h High-dose Cytarabine and Idarubicin in AML Follo...
(Date:11/19/2009)... World,s Top Gene Synthesis Compan...IGSC) to Coordinate Best Practices in Risk Reducti...f Worldwide Gene Synthesis Capacity , ...the world’s leading gene synthesis companies...common screening protocol to promote biosecurity i...
(Date:11/19/2009)... , VIENNA, Austria, November 19 /PRNewswire... program on one product candidate at an unexpected...te AD02 is planned to enter into,Phase II clinical...,immediately follows the completion of two Phase I...pany based its fast decision on the first interim,...
Breaking Biology Technology:Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3...will,grace the faculty of the "Pharma & Biotech Co...ence in two weeks in New Jersey. The conference is... Analysis, and Market,Forecasting executives; 200 ...-2 to attend the meeting. Competition has never be...or competitor moves in crowded,therapeutic classes...
... Measure Cardiac Output During Cardiop...ember 19 Cheetah Medical Inc.,developers of the C...me,cardiac output monitoring, announced at HFSA th...fficiency in heart failure are related to peak,exe...rd University and the VA Palo,Alto Health Care Sys...
...Ventures, Kleiner Perkins Caufie...of Technology Pioneer at Forefront of Developing N...EMERYVILLE, Calif., Sept. 19 Amyris Biotechnologi...ydrocarbon biofuels, today,announced that it close...nding. Duff Ackerman & Goodrich Ventures (DAG Vent...
Other Biology Technology:New Competitive Intelligence Speakers Spark Interest in Pharmaceutical Conference on October 1-2 in NJ 2Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting 2Cheetah Medical's NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting 3Amyris Biotechnologies Announces $70 Million Series B Round 2Rabbit Anti-Human MMP-13 Collagenase-3, amino terminal end of active enzyme, Antibody, Unconjugated from CEDARLANE Laboratories Limited
Mouse Anti-BCAR1 Monoclonal Antibody, Unconjugated, Clone SPM302 from Abcam
Anti-Phosphotyrosine IgG Monoclonal Antibody, Alkaline Phosphatase Conjugated, Clone AD548 from Assay Designs/Stressgen Bioreagents
Rabbit Anti-Myosin VIIa Polyclonal Antibody, Unconjugated from Abcam
Biology Products: